Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR Network Study

Competing Interest Statement

The authors have declared no competing interest.

Clinical Protocols

https://www.ecdc.europa.eu/en/publications-data/protocol-covid-19-vaccine-effectiveness-estimation-using-health-data-registries

Funding Statement

All the public health organizations involved received funding from the European Centre for Disease Prevention and Control (ECDC) implementing Framework Contract ECDC/2021/018 Vaccine effectiveness and impact of COVID-19 vaccines through routinely collected exposure and outcome using health registries (RS/2022/DTS/24104). In Portugal, this work was also supported by FCT Fundacao para a Ciencia e Tecnologia, I.P. by project reference CEECINST/00049/2021/CP2817/CT0001 and DOI identifier 10.54499/CEECINST/00049/2021/CP2817/CT0001

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All study sites participating in this study conformed with their respective national and EU ethical and data protection requirements. Ethical statements for each of the participating study sites: Belgium: Data linkage and collection within the data warehouse have been approved by the information security committee. The study was conducted in accordance with the Declaration of Helsinki. Ethical approval was granted for the gathering of data from hospitalized patients by the Committee for Medical Ethics from the Ghent University Hospital (reference number BC 07507) and authorization for possible individual data linkage using the national register number from the Information Security Committee (ISC) Social Security and Health (reference number IVC/KSZG/20/384). Linkage of hospitalized patient data to vaccination and testing within the LINK VACC project was approved by the Medical Ethics Committee UZ Brussels VUB on 3 February 2021 (reference number 2020/523), and authorization from the ISC Social Security and Health (reference number IVC/KSZG/21/034). Denmark: Only administrative register data was used for the study. According to Danish law, ethics approval is exempt for such research, and the Danish Data Protection Agency, which is dedicated ethics and legal oversight body, thus waives ethical approval for the study of administrative register data when no individual contact of participants is necessary, and only aggregate results are included as findings. The study is, therefore, fully compliant with all legal and ethical requirements, and there are no further processes available regarding such studies. Navarre (Spain): The study was approved by Navarre Ethical Committee for Clinical Research, which waived the requirement of obtaining informed consent. Norway: Ethical approval was granted by Regional Committees for Medical and Health Research Ethics (REC) Southeast (reference number 122745). The Norwegian Institute of Public Health has performed a Data Protection Impact Assessment (DPIA) for Beredt C19. Portugal: The study received approval from the Ethical Committee and the Data Protection Officer of the Instituto Nacional de Saude Doutor Ricardo Jorge. Given that data was irreversibly anonymised, the need for the participants informed consent was waived by the Ethical Committee. Italy: This study, based on routinely collected data, will not be submitted for approval to an ethical committee because the dissemination of COVID 19 surveillance data was authorized by the Italian law N. 52 of 19 May 2022, following the law decree N. 24 of 24 March 2022 (Article n. 13). Based on the same acts, the information on COVID-19 vaccination was retrieved by the Italian National Institute of Health using data from the National Immunisation Information System of the Italian Ministry of Health. Because of the retrospective design and the large size of the population under study, in accordance with the Authorization n. 9 released by the Italian data protection authority on 15 December 2016, the individual informed consent was not requested for the conduction of this study. Sweden: The Swedish study is approved by the Swedish Ethical Review Authority (2020 06859, 2021 02186) and has conformed to the principles embodied in the Declaration of Helsinki. Consent to participate is not applicable as this is a register based study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes